Showing papers on "Vaccination published in 1975"

Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants.

Abstract: Group A and group C meningoccal polysaccharide vaccines were evaluated in infants. No significant local or systemic reactions were observed with 908 doses of vaccine given to 396 infants between 3 and 12 mo of age. The antibody response varied with the age of the infant, vaccine dose, molecular weight of vaccine, prior immunization with vaccine, and prior exposure to naturally occurring cross-reactive antigens. Only 7% of 3-mo-old infants had detectable antibody responses to primary immunization with 5-200 mug of A vaccine, presumably because of suppressive effects of high concentrations of maternal anti-A. More than 90% of 7- and 12-mo-old infants responded to A vaccine, achieving geometric mean anti-A concentrations of 0.38 and 0.98 mug/ml, respectively. The dose-response curve was flat between 10 and 200 mug of A vaccine. Geometric mean anti-A concentrations of 2.51 and 4.00 mug/ml were induced in 7- and 12-mo-old infants by booster injections of A vaccine. Approximately 90% of 3-mo-old infants had detectable antibody responses to primary immunization with C vaccine. The 100-mug dose appeared to be optimal, resulting in geometric mean anti-C concentrations of 0.49, 1.55, and 2.64 mug/ml in 3-, 7-, and 12-mo-old infants, respectively. Significant booster responses were not observed with C vaccine. Indeed, except for the 10-mug dose, booster injections of C vaccine in 7- and 12-mo-old infants resulted in lower anti-C concentrations than did primary immunizations.

Differences in the Appearance of Antibodies to Structural Components of Measles Virus after Immunization with Inactivated and Live Virus

Abstract: Children immunized with inactivated (Tween 80 and diethyl ether, TE) measles vaccine, attenuated live vaccine, or a combination of the two types were studied with regard to the production of hemagglutination-inhibiting (HAI), hemolysis-inhibiting (HLI), and nucleocapsid complement-fixing (CF) antibodies. For identification of antibodies to envelope components distinct from hemagglutinin. HLI tests were done both before and after removal of HAI antibodies with TE-treated virus antigen. Immunization with three or four doses of TE vaccine led to the production of HAI antibodies and, in some cases, of nucleocapsid CF antibodies. Non-HAI HLI antibodies were not detected. In contrast, live vaccine caused the appearance of non-HAI HLI antibodies and, in the majority of cases, nucleocapsid CF antibodies. After combined immunization with TE vaccine and attenuated vaccine, non-HAI HLI antibodies were absent from 25 of 29 children. Most children exposed to wild measles virus after immunization with TE vaccine alone developed a poorer non-HAI HLI antibody response than children who had had normal measles. The latter infections resulted in a more pronounced non-HAI HLI and nucleocapsid CF antibody response than that observed after infections with vaccine virus. An even more accentuated response involving these antibodies was seen in patients with subacute sclerosing panencephalitis. Thus the failure of inactivated measles vaccines to prevent infection may be due to the absence of an envelope component responsible for the production of non-HAI HLI antibodies.

Smallpox vaccination reactions, prophylaxis, and therapy of complications

Abstract: Smallpox vaccination in the United States is a routine public health measure which has been under intensive review during the last decade. The most frequently occurring adverse reactions to vaccination are benign and require little or no systemic therapy. These reactions include accidental infection, erythematous and urticarial rash, and generalized vaccinia. Chickenpox occurring concurrently with vaccination presents no problem unless vaccinia has widely superinfected the chickenpox lesions. There is no risk to the pregnant woman who is vaccinated, but there is a slight risk that the fetus will develop fetal vaccinia. The vaccinia does not cause congenital malformations. Vaccinia hyperimmune globulin (VIG) in prophylactic dosage may be given to a pregnant woman who is traveling to a smallpox infected or endemic area in order to prevent fetal vaccinia. Vaccinia necrosum and eczema vaccinatum require vigorous systemic therapy with VIG, and often thiosemicarbazone. Post-vaccinial encephalitis, while frequently serious, has not been shown to be ameliorated by VIG therapy, although there are data which suggest VIG has some value in prophylaxis for encephalitis. Prophylaxis, prompt recognition, and proper therapy may reduce the fatality rates of these complications. Revaccination of patients who have suffered a complication is a frequent clinical problem. Revaccination of an individual who has had post-vaccinial encephalitis or vaccinia necrosum is contraindicated unless the risk of contracting smallpox outweighs the risk of the above two diseases. Revaccination of children who have had eczema vaccinatum is not contraindicated. Revaccination of children with a history of accidental infection or erythematous or urticarial rash presents no known or theoretically increased risk.

Smallpox eradication in West and Central Africa.

Abstract: In 1966, a programme to eradicate smallpox and control measles began in West and Central Africa. With WHO and US bilateral technical and financial assistance, the 20 countries mounted a coordinated campaign of mass vaccination, assessment, surveillance, and maintenance activities. The last cases of smallpox occurred in May 1970. The introduction of epidemiologically directed surveillance-containment activities and their rapid success resulted in interruption of smallpox transmission much sooner than anticipated. The area has remained free of smallpox. From 1966 to 1972, over 28 000 000 children 1-6 years of age also received measles vaccination. The campaign established or strengthened structures for preventive health care services in all the countries.

The minimum protective level of antibodies in smallpox.

Abstract: Blood samples from 57 contacts of 6 smallpox cases were tested for haemagglutination-inhibiting (HI) and neutralizing antibodies. All 6 contacts who subsequently developed smallpox were unvaccinated and had neutralizing antibody titres of 10 or less. However, 6 unvaccinated contacts with similar antibody levels did not develop smallpox. None of the 41 vaccinated contacts, regardless of their antibody level, contracted the disease.

Oral polio vaccination of children in the tropics. II. Antibody response in relation to vaccine virus infection.

Abstract: Poliovirus antibody response rates following the administration of trivalent oral polio vaccine (OPV) have been poor in several developing countries. In an attempt to determine if poor seroresponse is due to poor rates of vaccine virus "take" or due to poor serum antibody response to intestinal virus infection, both vaccine virus take and serum antibody response were determined in a group of children given two doses of OPV. In the large majority of seronegative children there was good correlation between the absence or presence of vaccine virus excretion and negative or positive seroconversion, thus showing that the poor seroconversion rates were mainly due to poor rates of vaccine virus take. However, as in several studies from developed countries showing good seroconversion rates, a few instances of antibody response in the absence of detectable virus excretion and fewer instances of virus excretion without detectable antibody response were also found.

Immunity to Marek's disease induced by glutaraldehyde-treated cells of Marek's disease lymphoblastoid cell lines

Abstract: MAREK'S disease (MD) is a common neoplastic disease of the domestic fowl caused by a herpesvirus (MDV). It is controlled in the field by vaccination with artificially attenuated strains of MDV, or more commonly with the antigenically related herpesvirus of turkeys (HVT)1. The nature of the immune prophylaxis is not clear; protective immunity may be directed against MDV, against the development of tumours, or both. One way in which vaccination may exert its effect is by influencing the spread of MDV within the body2. In contrast, infected birds may occasionally recover after showing signs of MD clinically, and in some birds MD lymphoproliferative lesions regress3, so it is likely that there is also an anti-tumour immune reaction. We have sought evidence for anti-tumour immunity in experimentally immunised birds.

In vitro correlates of cell-mediated immunity in human tonsils after natural or induced Rubella virus infection.

Abstract: The techniques of hemagglutination inhibition and in vitro lymphocyte transformation and the assay of migration inhibitory factor were used for study of the development of rubella antibody activity in serum and tonsillar tissue washings and of the appearance of rubella-specific, cell-mediated immunity in circulating and tonsillar lymphocytes in groups of children who underwent tonsillectomy at various intervals after natural rubella infection, subcutaneous immunization with HPV-77 DE/5 vaccine, or intranasal inoculation with RA27/3 live, attenuated rubella virus vaccine. Antibody response in serum and tonsillar tissue washings was detected regularly after natural infection or immunization. Development of specific cellmediated immunity in circulating lymphocytes was regularly observed after natural infection and frequently after immunization. Natural infection or intranasal immunization with rubella vaccine resulted in the appearance of cell-mediated immunity in the tonsillar lymphoid tissue, and the response was detectable up to several years after natural infection in several cases. It is significant, however, that the level of cell-mediated immunity in tonsils was conspicuously low after subcutaneous immunization. These data suggest the induction of local cell-mediated immunity in tonsillar lymphoid tissue after local mucosal application of rubella virus. It has been shown that nasopharyngeal antibody plays an important role in the protection against reinfection with rubella [1] and other viruses [2]. However, no information is available regarding the development and role of mucosal cellmediated immune responses and their participation in the mucosal immune function. We initiated the present studies to examine the appearance of the cell-mediated immune response in tonsillar lymphocytes to rubella virus after natural infection or immunization with live at

Influence of antibody-mediated immune suppression on clinical, viral, and immune responses to swine influenza infection.

Abstract: Antibody-mediated immune suppression occurred when newborn pigs with naturally acquired passive antibody were exposed to seine influenza virus. Frequency and relative ease of recovery of virus from nasal secretions were inversely related to the concentration of specific passive antibody existing at time of exposure. Severe overt respiratory signs during the acute stages of the disease were observed only in pigs with low passive antibody concentrations. The concentration of passive antibody at the time of exposure determined the immune status of the pig during the convalescent stage of disease. Infection could occur in the presence of high passive antibody concentrations, but the pig was not immunologically stimulated. Reexposure after the decay of passive antibody produced primary immune respone, severe clinical reinfection, and recovery of virus from nasal secretions for a period of time similar to that seen in pigs having their first exposure. Infection of newborn pigs with low passive antibody concentrations led to immunologic priming. A second exposure to virus produced a secondary immune response, mild clinical disease, and shortened time during which virus was recovered from nasal secretions. The relevance of these studies for the practice of vaccination or infections of the dam before parturition so that the neonate will have specific passive immunity is discussed.

Measles mortality: a retrospective look at the vaccine era.

Abstract: Barkin, R. M. (Bureau of Epidemiology, CDC, Atlanta, GA 30333). Measles mortality: A retrospective look at the vaccine era. Am J Epidemiol 102:341-349, 1975. Measles mortality provides an indicator in defining the population at greatest risk of experiencing serious complications from measles as well as serving as a parameter in assessing the impact of immunization programs. Efforts to vaccinate susceptible children have helped to reduce measles morbidity and mortality in the United States. Mortality rates were highest in children 6-11 months of age. Higher mortality rates were noted in places with less than 10,000 people and in counties having a large percentage of the population with incomes below poverty level. Vaccine should be accessible to all populations, but intensive efforts need to be directed toward groups at high risk of dying from measles who are suffering from a myriad of other health, social, and economic problems.

Epidemiology of congenital rubella syndrome. The role of maternal parity.

Abstract: Rubella vaccination policies are primarily directed at control of congenital rubella syndrome. In the United States, vaccination of children of both sexes, ages 1 through 12 years, has been recommended. This policy depends on the hypothesis that children are the major source of infection for pregnant women. If true, then as maternal parity increases one would expect an increasing prevalence of rubella antibody or an increase in the frequency of rubella syndrome in babies. A serologic survey of 3,081 pregnant women has failed to show an increase in prevalence of rubella antibody with increasing parity. Case-control studies comparing groups of children with rubella syndrome to birth certificate and hospital control groups also have failed to show an excess of multiparae among the mothers of babies with rubella syndrome. Thus, these results do not support the hypothesis that children are the major source of infection for pregnant women. ( JAMA 233:151-155, 1975)

Long-Term Follow-up for Immunity After Monovalent or Combined Live Measles, Mumps, and Rubella Virus Vaccines

Abstract: Antibody in human subjects persisted without substantial decline for 8 years after mumps vaccine (Jeryl Lynn), for 6 years after measles (Attenuvax), for 5 1/2 years after rubella vaccine (HPV-77 duck), for 5 years after measles-mumps-rubella and mumps-rubella combined vaccines, for 4 years after measles and rubella, and for 2 years after measles-mumps vaccines, the longest periods tested. Protective immunity against mumps illness persisted through the eighth year. The patterns for antibody following vaccination parallel those for natural infection and indicate that immunity will be lasting. Subclinical reinfection evidenced by antibody increase was commonly seen in persons who had been vaccinated, much as follows the natural infection.

Vaccination of foxes against rabies using ingested baits

Abstract: A method for immunizing foxes against rabies was evaluated. Fifteen of 36 red foxes (Vulpes fulva) fed baits impregnated with modified live virus rabies vaccine developed serum rabies neutralizing antibody. The vaccine-bait proved unstable when held at 4 C or 25 C for 96 hours prior to feeding. For safety testing the vaccine virus was administered to opossums (Didelphis virginiana), cotton rats (Sigmodon hispidus), hamsters (Mesocricetus auratus), and chickens (Gallus domesticus) in either liquid or bait form. One of ten cotton rats fed liquid vaccine died of vaccine induced rabies. No animals which ate the vaccine-baits died of vaccine induced rabies.

Lymphocyte responses to rubella antigen and phytohemagglutinin after administration of the RA 27/3 strain of live attenuated rubella vaccine.

Abstract: Lymphocyte phytohemagglutinin (PHA) responsiveness was found suppressed in both rubella sero-negative and sero-positive recipients of RA 27/3 strain of live attenuated rubella vaccine; the suppression was readily demonstrable only when a suboptimal dose of PHA was applied in the test. Lymphocytes from sero-negative vaccinees, which initially showed little or no in vitro response to concentrated rubella virus, became responsive after vaccination by day 21, when the highest sensitization to rubella antigen was seen. In the sero-positive vaccinees. lymphocytes responded to rubella antigen in vitro before vaccination, and in most cases vaccination did not result in significant changes in lymphocyte response. These results suggest that rubella vaccination leads to temporarily increased lymphocyte reactivity to rubella antigen, and the increased lymphocyte response to specific antigen may occur at the time of mild suppression of PHA response.

Oral polio vaccination of children in the tropics iii. intercurrent enterovirus infections, vaccine virus take and antibody response

Abstract: The effect of intercurrent enterovirus infections on host responses to oral polio vaccine (OPV) was studied in groups of infants and children who were without antibodies to one, two or three serotypes of poliovirus. The prevalence of enterovirus infections as detected in fecal specimens collected at weekly intervals and inoculated in primary monkey kidney cell culture, HEp 2 cells and newborn mice ranged between 60 and 70 per cent. The presence of such infections at the time of, 1 week prior to, or during the 3 weeks prior to the administration of OPV did not appear to inhibit either vaccine virus take or antibody response. However, in both the infected and uninfected children the rates of vaccine virus take and seroconversion were found to be considerably lower than those reported from several temperate climate countries.

Depressed lymphocyte function after measles-mumps-rubella vaccination.

Abstract: Healthy children receiving routine measles-mumps-rubella vaccine developed an impaired in vitro lymphocyte response to stimulation with antigen (Candida) but not with mitogen (phytohemagglutinin and pokeweed mitogen) Response of lymphocytes was determined by measurement of the amount of [14C]thymidine incorporated by the cells The impaired response to antigen lasted from one to five weeks after vaccination There was no alteration in the number of either total or thymus-derived lymphocytes in the peripheral blood after vaccination; These results suggest that viral vaccination causes a depression of lymphocyte function rather than a depletion of functional lymphocytes

The present status of vaccination against coccidioidomycosis in man

Abstract: Vaccines of killed whole cells of Coccidioides immitis have been injected intramuscularly in 97 human subjects to determine the safety and tolerable dose of vaccine and certain immunologic responses. Seventy-eight individuals received the whole killed spherule preparation; 18 received killed mycelial vaccine. The maximum tolerable dose of spherule vaccine was approximately 5 mg. Systemic effects were slight though in two prior coccidioidin reactors a moderate febrile illness and sbustantial antibody production followed vaccination with killed spherules. The vaccines irregularly induced antibody or delayed hypersensitivity to coccidioidin or spherule antigen. Greater antigenic mass perhaps as a soluble preparation may be needed for consistent immunologic stimulation though the spherule vaccine may be protective despite absence of detectable antibody or sensitivity to coccidioidin.

Determination of the site of oral rabies vaccination

Abstract: Foxes developed serum neutralizing antibodies to rabies only after oral administration of an attenuated rabies vaccine, and not when a similar vaccine dose was introduced into the stomach. These results emphasize the need for a bait that assures delivery of a vaccine dose orally.

Duration of antibody responses after vaccination with group C Neisseria meningitidis polysaccharide.

Abstract: Persistence of serum antibodies after vaccination with group C Neisseria meningitidis polysaccharide was followed in 23 volunteers. Each subject had received a single 50-jug dose of vaccine subcutaneously or intradermally one to five years earlier. Three individuals received a second inoculation eight months after the primary one with no evidence of booster antibody response. Hemagglutination antibody titers rose significantly in 22 of 23 volunteers within two to four weeks of injection; mean titers fell two- to threefold within the first year and then remained stable for four years. Bactericidal tests showed antibody response in 86% of subjects and antibody persistence comparable to that found in the hemagglutination tests. Titers of radioactive antigen-binding antibodies increased significantly in all 22 subjects tested, and after two to four years titers remained at 30% or more of peak concentration. The prolonged duration of antibody responses to polysaccharides in humans suggests that immunity will also persist. Purified group A and C meningococcal polysaccharides have been shown to be immunogenic in humans [1-4] and to be highly effective as prophylaxis against disease caused by Neisseria meningitidis [5, 6]. Among the questions that remain to be answered concerning these vaccines is the duration of the induced immunity. Since serum antibodies appear to be the determinants of human immunity to N. meningitidis [7], we have carried out long-term studies of volunteers who received group C polysaccharide vaccines. The results suggest that proteetive antibodies persist for at least five years after a single injection of vaccine.

Human responses to two decavalent rhinovirus vaccines.

Abstract: Two formalin-inactivated, decavalent rhinovirus vaccines were tested in humans for acceptability and antigenicity. Infectivity titers of the vaccine antigens were low and ranged from 10(1.5) to 10(5.5) 50% tissue culture infective doses/ml. There were minimal or no side effects to either vaccine. The first inoculation of one vaccine produced antigenic responses to 30% of the administered antigens. Limited testing for heterologous antibody responses to nonvaccine antigens showed scattered responses. These findings suggest that potent multivalent rhinovirus vaccines containing antigens selected for cross-reactivity should be tested in an attempt to develop practical control measures for rhinoviruses.

Potential for polyvalent infectious bronchitis vaccines.

Abstract: Numerous antigenic types and subtypes of infectious bronchitis virus (IBV) have been isolated and characterized from field epornitics of infectious bronchitis (IB). Thus obvious failures in obtaining the necessary protection from vaccination have been documented and they underscore the urgent need for vaccines which stimulate a broader spectrum of protection from heterologous IBV challenge than is presently obtained. If polyvalent IB vaccines are to be employed, assurance must be provided that variant IBV serotypes are not indiscriminately spread throughout the country or globe. Furthermore, possible interference, alteration, and reduction in immune response with the component antigens should be critically evaluated. Differences and comparative levels of postvaccinal respiratory signs with the different antigens, used singly and in combination, should be determined. As an alternative to polyvalent IB vaccines, certain Massachusetts-type strains, e.g., a Holland isolate IBV, at different passage levels in the authors' laboratory, have induced heterologous and homologous protection to some serotypes causing vexing field problems. Advantages are present in using a single antigenic type IB vaccine, if it is safe and effective, when compared to polyvalent vaccines. The absence of a serologic relationship to the results of immunity challenge is frequent with IBV isolates, which emphasizes that challenge results are considerably more important. In some IB problems, on a local or regional basis, autogenous vaccines may be indicated. Because of the multiplicity of IBV serotypes, however, it is doubtful that completely effective and safe IB vaccines will be forthcoming in the near future to satisfy the diverse needs of a dynamic poultry industry.